0.9178

0.90% 0.0082

After Hours: .92 0.0022 +0.24%

Fractyl Health Inc (GUTS)

Overview News Price History Discussions Forecast

Fractyl Health Inc stock is traded at $0.9178, with a volume of 1.70M. It is up +0.90% in the last 24 hours and up +48.03% over the past month. Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.

Previous Close:

$0.9096

Open:

$0.91

24h Volume:

1.70M

Relative Volume:

0.77

Market Cap:

$145.61M

Revenue:

$3,000

Net Income/Loss:

$-140.95M

P/E Ratio:

-0.4488

EPS:

-2.0449

Net Cash Flow:

$-90.89M

1W Performance:

+12.32%

1M Performance:

+48.03%

6M Performance:

-37.99%

1Y Performance:

-49.01%

1-Day Range:

$0.866

$0.9199

1-Week Range:

$0.795

$0.95

52-Week Range:

$0.3772

$3.03

Fractyl Health Inc Stock (GUTS) Company Profile

Name

Fractyl Health Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

781-902-8800

Address

3 VAN DE GRAAFF DRIVE, BURLINGTON

Employee

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

GUTS's Discussions on Twitter

Compare GUTS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GUTS Fractyl Health Inc	0.9178	144.31M	3,000	-140.95M	-90.89M	-2.0449
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-15-25	Initiated	H.C. Wainwright	Buy
Aug-28-25	Initiated	Ladenburg Thalmann	Buy
Feb-28-24	Initiated	Evercore ISI	Outperform
Feb-27-24	Initiated	BofA Securities	Buy
Feb-27-24	Initiated	Morgan Stanley	Overweight

View All

Fractyl Health Inc Stock (GUTS) Latest News

May 25, 2026

Earnings call transcript: Fractyl Health Q1 2026 reports EPS beat, shares surge - Investing.com

May 19, 2026

May 17, 2026

Fractyl targets early Q4 2026 REMAIN-1 pivotal readout amid plans for late Q4 2026 de novo submission - MSN

May 17, 2026

May 16, 2026

Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround - Yahoo Finance

May 16, 2026

First human GLP-1 gene therapy trial gets green light - The Hill

May 16, 2026

May 15, 2026

Nantahala’s 16.1M-share stake disclosed in Fractyl Health (NASDAQ: GUTS) - Stock Titan

May 15, 2026

[SCHEDULE 13G/A] FRACTYL HEALTH, INC. Amended Passive Investment Disclosure - Stock Titan

May 15, 2026

BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating, Announces Target Price $2 - Moomoo

May 15, 2026

May 14, 2026

Fractyl Health (GUTS) stock jumps 21% after hours: Here's what you should know - MSN

May 14, 2026

TradingKey - TradingKey

May 14, 2026

A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income - Yahoo Finance

May 14, 2026

Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), UnitedHealth (UNH) and TELA Bio (TELA) - The Globe and Mail

May 14, 2026

GUTS Stock Chart | FRACTYL HEALTH INC (NASDAQ:GUTS) - ChartMill

May 14, 2026

May 13, 2026

SilverArc and Devesh Gandhi report 3.6M shares in Fractyl Health (GUTS) - Stock Titan

May 13, 2026

Fractyl Health | 10-Q: Q1 2026 Earnings Report - Moomoo

May 13, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

May 13, 2026

Morgan Stanley Maintains Fractyl Health(GUTS.US) With Hold Rating, Maintains Target Price $2 - Moomoo

May 13, 2026

Earnings call transcript: Fractyl Health Q1 2026 sees EPS beat, stock rises By Investing.com - Investing.com India

May 13, 2026

May 12, 2026

Fractyl Health Q1 2026 Earnings Call Transcript - MarketBeat

May 12, 2026

Fractyl Health Q1 Earnings Call Highlights - sharewise.com

May 12, 2026

Earnings call transcript: Fractyl Health Q1 2026 sees EPS beat, stock rises - Investing.com

May 12, 2026

Fractyl Health Q1 2026 Earnings Call: Complete Transcript - Benzinga

May 12, 2026

Fractyl Health Inc (NASDAQ:GUTS) Q1 Earnings: Net Income Swing Masks Core Operating Burn as Key Revita Data Readout Looms - ChartMill

May 12, 2026

FRACTYL HEALTH ($GUTS) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative

May 12, 2026

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates - The Manila Times

May 12, 2026

Fractyl Health 1Q 2026: Net income $9.22M, EPS $0.06— 10-Q Summary - TradingView

May 12, 2026

Fractyl Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 12, 2026

Fractyl Health (NASDAQ: GUTS) posts Q1 2026 profit but flags going concern risk - Stock Titan

May 12, 2026

Fractyl Health (Nasdaq: GUTS) Q1 2026 results, Revita pivotal and Rejuva CTA - Stock Titan

May 12, 2026

Fractyl Health’s RJVA-001 cleared to enter clinic in Netherlands - BioWorld News

May 12, 2026

GUTS EarningsMAR/2026 AI PredictionIntellectia AI™ - Intellectia AI

May 12, 2026

May 11, 2026

Fractyl Health receives approval for gene therapy diabetes trial By Investing.com - Investing.com Australia

May 11, 2026

Fractyl Health Receives Approval to Launch First-in-Human Gene Therapy Clinical Trial for Type 2 Diabetes in the Netherlands 1 - Minichart

May 11, 2026

Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial - BioPharma Dive

May 11, 2026

Fractyl Health Advances RJVA-001 Gene Therapy Trial - TipRanks

May 11, 2026

Fractyl Health receives approval for gene therapy diabetes trial - Investing.com

May 11, 2026

Fractyl Health (NASDAQ: GUTS) wins OK for first-in-human RJVA-001 gene therapy trial - Stock Titan

May 11, 2026

Fractyl Health Authorized to Initiate First-in-Human Trial - GlobeNewswire

May 11, 2026

May 08, 2026

Fractyl Health Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView

May 08, 2026

May 05, 2026

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference - The Manila Times

May 05, 2026

Fractyl Health to Report First Quarter 2026 Financial - GlobeNewswire

May 05, 2026

Apr 29, 2026

GUTS Stock Price, Quote & Chart | FRACTYL HEALTH INC (NASDAQ:GUTS) - ChartMill

Apr 29, 2026

Apr 28, 2026

Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Down 34.7% in April - MarketBeat

Apr 28, 2026

Apr 27, 2026